VC firm RA Capital starts a new synthetic biology incubator
By Allison DeAngelis July 27, 2023
Venture capital firm RA Capital is starting a new incubator, setting the stage for the firm to create new startups over the next several years that hone in on synthetic biology, a long-gestating field that insiders say is getting renewed interest.
The Boston-based VC’s incubator is called RASyn, and will be led by Robert Nicol, according to people familiar with the firm’s plans. Nicol spent more than 20 years at the Broad Institute, where he co-founded the MIT-Broad Foundry for Synthetic Biology, as well as HiFiBio Therapeutics and Design Pharmaceuticals.
RA Capital confirmed RASyn’s existence. Senior Managing Director Josh Resnick told STAT it’s part of the firm’s work to rethink how it develops platforms — core technologies or scientific approaches that underpin all of the drugs a biotech develops — but declined to comment further.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
Biotech Startups and Venture Capital Reporter
Allison DeAngelis is a biotech reporter at STAT, covering biopharma startups and venture capital.
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.Exciting news!